Social media

On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP‑1‑Based Therapeutics Summit for his session, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He will offer a fo...

An estimated one billion people worldwide will be living with obesity by 2030. Discover how we deliver ready-to-deploy infrastructure, market intelligence, and deep expertise to support early decisions and accelerate h...

Recent findings highlight the continued relevance and reliability of the Oswestry Disability Index instrument for evaluating disability in patients with Degenerative Disc Disease. Study participants demonstrated strong...

Recent findings highlight the continued relevance and reliability of the Oswestry Disability Index instrument for evaluating disability in patients with Degenerative Disc Disease. Study participants demonstrated strong c...

ICON proudly supports #WorldObesityDay. An estimated one billion people worldwide will be living with obesity by 2030. Explore how we support next‑generation obesity trials by delivering market intelligence and ready‑t...

Neuroscience programmes demand reliable feasibility, broad patient access, and operational consistency across regions. At ADPD 2026, stop by booth \#29 to learn how ICON combines informatics driven feasibility, extensi...

On 17-21 March at #ADPD2026, visit us at booth #29 to speak with our experts to learn how ICON is working to improve drug development and advance treatments for Alzheimer’s and Parkinson's disease and other movement diso...

Clinical trial start-up can be a stubborn bottleneck, where delays can cost time, money, and patient access. ICON’s industry survey and commentary from Brian Mallon, EVP of Site and Patient Solutions, reveal why timeline...

Clinical trial start-up can be a stubborn bottleneck, where delays can cost time, money, and patient access. ICON’s industry survey and commentary from Brian Mallon, EVP of Site and Patient Solutions, reveal why timeline...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Ahead of World Obesity Day tomorrow, explore how ICON successfully supported a sponsors cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate ...